
Opinion|Videos|March 20, 2025
Examining the 505(b)(2) Pathway and Implementation into EHR
A panelist discusses how the 505(b)(2) regulatory pathway provides a streamlined approval process for modified versions of previously approved drugs, allowing pharmaceutical companies to rely partly on existing safety/efficacy data while still requiring new clinical data, commonly used across various therapeutic areas including reformulations, new dosage forms, and drug combinations.
Advertisement
1:14 505(b)(2) Pathway Introduction
6:33 Role of Pharmacists
11:48 505(b)(2) in Oncology
26:00 Medication Management
32:34 Leveraging EHR
44:24 Unmet Needs
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Research Finds No Clinically Important Increase in Autism, ADHD Following Prenatal Paracetamol Use
2
Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events
3
Incretin-Based Drugs May Reduce Risk of Dementia in Patients With Type 2 Diabetes
4
Address Health Disparities Through Pharmacist-Led Initiatives in Underserved Communities
5











































































































































































































